The virus could replicate. It could infect other people.
A pesquisa conduzida pelo Instituto de Medicina Tropical da USP revela que o SARS-CoV-2 pode permanecer vivo e transmissível muito além do período de isolamento de 14 dias adotado pelo Brasil — uma descoberta que questiona uma das premissas centrais das políticas de saúde pública durante a pandemia. Em dois casos documentados, o vírus seguia replicando ativamente entre 22 e 37 dias após o início dos sintomas, em pacientes com quadros considerados leves. A ciência, mais uma vez, nos lembra que as regras que criamos para conter o invisível precisam ser constantemente revisadas diante da realidade que ele nos apresenta.
- O vírus foi confirmado como viável e capaz de infectar outras pessoas em amostras coletadas semanas após o início dos sintomas — muito além do que os protocolos atuais preveem.
- 6% dos participantes monitorados permaneceram infecciosos por mais de 14 dias, e em 18% o RNA viral foi detectável por até 50 dias, revelando uma lacuna real nas diretrizes de isolamento.
- A replicação prolongada do vírus dentro do hospedeiro aumenta as chances de mutação, criando condições para o surgimento de variantes com potencial vantagem adaptativa.
- Populações imunossuprimidas — incluindo pacientes com doenças autoimunes em tratamento — estão particularmente expostas, mas frequentemente não recebem o monitoramento adequado.
- Os pesquisadores alertam que as diretrizes de isolamento, pensadas para o caso típico, podem precisar de revisão para proteger os grupos mais vulneráveis.
Pesquisadores do Instituto de Medicina Tropical da USP documentaram algo que desafia uma premissa central da resposta à pandemia: o vírus causador da COVID-19 pode permanecer vivo e transmissível por muito mais tempo do que o período de isolamento padrão adotado pela maioria dos países.
O estudo acompanhou duas mulheres na faixa dos cinquenta anos que contraíram o vírus em 2020. A primeira testou positivo mais de três semanas após o início dos sintomas, e quando foi testada novamente 37 dias depois, o vírus ainda estava presente. A segunda apresentou resultado positivo cinco dias após adoecer, e um novo teste 24 dias depois confirmou a persistência da infecção. O que tornou esses casos especialmente relevantes foi a análise laboratorial das amostras: colocadas em culturas de células epiteliais, o vírus demonstrou ser viável — capaz de replicar e infectar outras pessoas.
As duas pacientes faziam parte do Programa Corona São Caetano, uma plataforma de monitoramento remoto com 50 participantes. Os dados do grupo revelaram um padrão preocupante: em 18% dos voluntários, o teste PCR permaneceu positivo por até 50 dias, e 6% continuaram ativamente infecciosos por mais de 14 dias — justamente o período de isolamento recomendado no Brasil para casos leves.
A pesquisadora Maria Cassia Mendes-Correa destacou dois riscos adicionais: a replicação prolongada favorece o surgimento de mutações virais, e populações com imunossupressão moderada — como pacientes com doenças autoimunes — estão mais vulneráveis, mas frequentemente não recebem monitoramento equivalente. Os casos documentados parecem atípicos, mas sua existência exige uma reavaliação das diretrizes baseadas no prazo de 14 dias, especialmente para proteger os grupos mais frágeis.
Researchers at the University of São Paulo's Institute of Tropical Medicine have documented something that challenges a foundational assumption of pandemic response: the virus that causes COVID-19 can remain alive and capable of spreading for far longer than the standard isolation period most countries have adopted.
The finding emerged from a careful study of two women in their fifties who contracted the virus in 2020. The first woman tested positive in April, more than three weeks after her symptoms began. She experienced nausea, vomiting, and loss of taste and smell—symptoms that eventually resolved. But when she was tested again 37 days after her initial symptoms appeared, the virus was still there. Full recovery took until mid-May. The second woman fell ill in May with fever, headache, cough, weakness, and body aches. Her first test came five days into illness and was positive. A second test 24 days later showed the virus persisting.
What made these cases significant enough to warrant deeper investigation was not just their duration but what the researchers found when they looked more closely. Maria Cassia Mendes-Correa, who led the research, explained that samples of nasal and throat secretions were sent to the institute for detailed analysis. The material was placed in cultures of epithelial cells—the tissue that lines the respiratory tract. After running multiple tests, the team confirmed something crucial: the virus present in those samples was still viable. It could replicate. It could infect other people.
These two women were part of a larger monitoring effort called the Corona São Caetano Program, an online platform designed to track residents with COVID symptoms remotely and collect samples from home for testing. Fifty people participated in the broader study. Among them, the data revealed a troubling pattern. Viral RNA remained detectable in saliva and nasal secretions for extended periods. In 18 percent of volunteers, the standard PCR test stayed positive for up to 50 days. More critically, 6 percent of those monitored remained actively infectious—meaning the virus was still replicating inside them—for longer than 14 days.
This matters because 14 days is the isolation period Brazil recommends for people diagnosed with mild COVID-19. If the virus can remain transmissible beyond that window, then people who follow the guidelines and return to normal activity may still be spreading infection. The implications ripple outward in ways both immediate and concerning.
Mendes-Correa pointed to a secondary danger: prolonged viral replication inside a host creates conditions for the virus to mutate. The longer it multiplies, the more chances it has to develop variations that might give it advantages. The patients in this study who showed extended viral persistence had significant immune suppression and were being closely monitored under research protocols. But the researcher emphasized that concern should extend beyond such extreme cases. People with milder forms of immune compromise—those with autoimmune diseases taking immunosuppressive medications, for instance—also face heightened risk. They represent a substantial portion of the population, yet they may not receive the same level of monitoring or protection.
The study does not suggest that everyone infected with COVID will shed the virus for weeks. The cases documented here appear to be atypical. But their very existence forces a recalibration of assumptions. Standard isolation periods, designed for the typical case, may leave gaps for vulnerable populations. And the possibility of extended transmission, even in a minority of cases, means that public health guidance built on a 14-day assumption may need revision.
Notable Quotes
The virus present in those samples was still viable. It could replicate. It could infect other people.— Maria Cassia Mendes-Correa, lead researcher
Prolonged viral replication increases the chances for the virus to develop mutations that might give it advantages, particularly concerning for immunocompromised populations.— Maria Cassia Mendes-Correa
The Hearth Conversation Another angle on the story
Why does it matter if the virus stays active longer than 14 days if the person's symptoms have resolved?
Because the virus being active means it can still replicate and spread to others. A person can feel fine, return to work or see family, and unknowingly transmit infection. The symptom timeline and the viral timeline are not the same thing.
Were these two women exceptional cases, or is this common?
The study suggests they were atypical—the researchers specifically note that. But they found the same pattern in 6 percent of their 50 monitored patients. That's a small fraction, but it's not zero. And we don't know how many people in the broader population might fall into that category.
What's the danger of the virus replicating for so long inside one person?
The longer it multiplies, the more mutations it can develop. Most mutations are harmless or even disadvantageous to the virus, but some might make it more transmissible or harder to treat. You're essentially giving the virus more chances to evolve.
Who is most at risk from this prolonged shedding?
People whose immune systems are already compromised—those with autoimmune diseases on immunosuppressive drugs, for example. Their bodies can't clear the virus as efficiently, so it lingers longer. But they're also the people least able to handle severe infection if they catch it again.
Does this mean the 14-day isolation rule is wrong?
Not wrong exactly, but incomplete. It works for most people. But for a subset of the population, it's not enough. The question is whether public health guidance should be adjusted to account for that minority, or whether we need different protocols for different groups.
What happens next?
That's the open question. The research is documented, the risk is identified. Now it's up to health authorities to decide whether isolation guidelines need revision, and whether immunocompromised patients need special monitoring or extended isolation periods.